Advertisement

Topics

Boehringer Ingelheim & Lilly Back the ACC in Addressing CVD Risk in Diabetes

08:05 EDT 2 Aug 2017 | PharmPro

Boehringer Ingelheim and Lilly to support new American College of Cardiology program to highlight the increasingly important role of cardiologists in reducing cardiovascular risk and cardiovascular death in people with type 2 diabetes.
Contributed Author: 
PR Newswire
Topics: 

Original Article: Boehringer Ingelheim & Lilly Back the ACC in Addressing CVD Risk in Diabetes

NEXT ARTICLE

More From BioPortfolio on "Boehringer Ingelheim & Lilly Back the ACC in Addressing CVD Risk in Diabetes"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Lilly
Eli Lilly and Company was founded in 1876, and is now the 9th largest pharmaceutical company based an annual sales which were just under $20bn in 2009. Orginally from the USA, Lilly now operates in over 50 countries with just under 40,000 employees. Appr...

Cardiology
Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...